Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Jan;23(1):e43-e46.
doi: 10.1111/hae.13131. Epub 2016 Dec 11.

Pilot randomized, non-inferiority, cross-over trial of once-weekly vs. three times-weekly recombinant factor VIII prophylaxis in adults with severe haemophilia A

M V Ragni  1   2 , J G Yabes  3 , P F Fogarty  4 , N C Josephson  5 , C M Kessler  6 , A T Neff  7 , L Raffini  8 , K Brummel-Ziedins  9 , C G Moore  3
Affiliations
Randomized Controlled Trial

Pilot randomized, non-inferiority, cross-over trial of once-weekly vs. three times-weekly recombinant factor VIII prophylaxis in adults with severe haemophilia A

M V Ragni et al. Haemophilia. 2017 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

of Conflict of Interest: MVR has received research funding from Alnylam, Baxalta, Biogen, CSL Behring, Dimensions, Genentech/Roche, Pfizer, Shire, SPARK; and honoraria for consulting for Alnylam, Baxalta, Biogen, Biomarin, and Tacere Benitec. PFF has received research funding from Baxter, Bayer, Biogen, CSL Behring, Pfizer; and SPARK Therapeutics; and advisory board fees from Bayer, Baxter/Baxalta, Biogen, Chugai, CSL Behring, Novo Nordisk, and Pfizer; and is an employee of Pfizer. CMK has received research funding from Bayer, NovoNordisk, Octapharma, Roche, and Shire; and acted as a paid consultant for Bayer, Biogen, Grifols, Octapharma, Pfizer, Roche Shire. ATN has received fees as a member of an advisory board for Shire. NCJ, LR, JGY, KBZ, and CGM declare no competing interests.

Figures

Figure 1
Figure 1. Hemophilia Adult Prophylaxis Trial Flow Diagram
The flow diagram includes numbers of subjects screened, excluded, randomized, completed treatment, and included in analysis.
See this image and copyright information in PMC

References

    1. Rosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia. 2006;12(Suppl 3):117–121. - PubMed
    1. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson L, Funk S, Jacobon L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros d, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535–544. - PubMed
    1. National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) Recommendation No. 179. MASAC Recommendation concerning prophylaxis: regular administration of clotting factor concentrate to prevent bleeding. http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contenti....
    1. Tagliaferri A, Franchini M, Coppola A, Rivolta GF, Santoro C, Rossetti G, Feola G, Zanon E, Dragani A, Iannaccaro P, Radossi P, Mannucci PM. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia. 2008;14:945–951. - PubMed
    1. Centers for Disease Control and Prevention. [accessed March 15, 2010];Bleeding and clotting disorders surveillance. Summary report of UDC activity. http://www2a.cdc.gov/ncbddd/htcweb/index.asp.